Prof. Zhigao Li 李志高
Chief Physician, Professor
Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Breast cancer surgery including endoscopic breast-conserving and nipple-sparing procedures, immediate implant reconstruction, and complex autologous reconstruction (TRAM, DIEP, latissimus dorsi flaps). Management of benign tumors, mastitis, early diagnosis, and systemic therapies such as chemotherapy, endocrine therapy, and targeted therapy.
Dr. Li is a Chief Physician and Professor at Harbin Medical University Cancer Hospital. Dr. Li holds a medical doctorate and completed postdoctoral training at Harbin Medical University, with fellowships at Toronto General Hospital and the University of Pittsburgh Medical Center. Since 1987, Dr. Li has specialized in breast and digestive tract tumors, pioneering endoscopic breast surgery in Heilongjiang Province.
Professional roles
- Standing Committee Member, Breast Cancer Professional Committee, China Anti-Cancer Association
- Standing Committee Member, Integrated Onco-Cardiology Professional Committee, China Anti-Cancer Association
- Chair, Breast Branch, Heilongjiang Medical Doctor Association
- Vice Chair, Breast Branch, Heilongjiang Medical Association
Name order: in Chinese the family name comes first (Li Zhigao). Papers usually list the name as Zhigao Li or Li Z.
Selected publications
27 papers on PubMed matched by name and affiliation; 13 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cancer Cell Int, 2024 (senior author): Unveiling heterogeneity and prognostic markers in ductal breast cancer through single-cell RNA-seq. PubMed 39068476
- Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, 2024 (senior author): [Effectiveness of sequential method pure single-port lumpectomy-breast conserving surgery for early-stage breast cancer in different quadrants]. PubMed 39013814
- Breast Cancer Res Treat, 2024 (senior author): Correction: FN1-mediated activation of aspartate metabolism promotes the progression of triple-negative and luminal a breast cancer. PubMed 38153570
- Breast Cancer Res Treat, 2023 (senior author): FN1 mediated activation of aspartate metabolism promotes the progression of triple-negative and luminal a breast cancer. PubMed 37458908
- Transl Oncol, 2023 (senior author): Cancer stem cells promote lymph nodes metastasis of breast cancer by reprogramming tumor microenvironment. PubMed 37421907
- Medicina (Kaunas), 2023 (senior author): Identification of Genes Associated with Prognosis and Immunotherapy Prediction in Triple-Negative Breast Cancer via M1/M2 Macrophage Ratio. PubMed 37512096
- Front Oncol, 2021 (senior author): Research Progress on the Role of Regulatory T Cell in Tumor Microenvironment in the Treatment of Breast Cancer. PubMed 34868991
- J Bioenerg Biomembr, 2020 (senior author): Downregulated PEG3 ameliorates cardiac fibrosis and myocardial injury in mice with ischemia/reperfusion through the NF-κB signaling pathway. PubMed 32350757
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion